Head of the "Immunology of skin allergy and vaccination"
Team Unit 1111 / JRU 5308 International Center for Infectiology Research (CIRI)
+33 (0)4 37 28 23 48
Why do eczema patches caused by skin contact with an allergen reappear in the same areas despite having had time to heal? This is what an International Center for Infectiology Research team with members from Inserm, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon and CNRS were keen to find out. The researchers discovered that not only do the allergens persist in the skin for several weeks but also that they are not alone in doing so. Indeed, immune cells – known as tissue-resident memory T cells – proliferate at the lesion sites and remain there for long periods, reactivating the onset of eczema patches in the event of re-exposure to the allergen. This research, published in The Journal of Allergy and Clinical Immunology, opens up new perspectives when it comes to understanding the mechanism and treatment of allergic contact dermatitis.
Allergic contact dermatitis (ACD) (a type of eczema) is a skin reaction triggered by exposure to allergens. The resulting inflammation of the upper layers of the skin can last for several days, persists for as long as the area remains in contact with the allergen in question and can even become chronic. It manifests as localized skin rashes (eczema patches) accompanied by itching and burning, and reappears if the healed areas are re-exposed to the allergen.
Tissue-resident memory T (TRM) cells are immune cells that persist in peripheral tissues, such as the skin, over the long term. They contribute to the secondary immune response that – while especially rapid and effective against pathogens encountered previously – can cause the exacerbation of some inflammatory diseases, such as ACD. In the eczema patches caused by ACD, a build-up of TRMs is indeed observed.
A research team at the International Center for Infectiology Research (CIRI), with members from Inserm, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon and CNRS, studied the contribution of TRMs to the severity and chronicity of ACD in mice. They observed that the TRMs proliferate locally in the areas of the skin in contact with the allergen.
Finally, the researchers observed that the reactivation of the TRMs responsible for the eczema patches was subject to a retro-control enabled by a specific set of inhibitory receptors carried by the TRMs. When re-exposed to a low dose of allergen, these receptors are activated and suppress the activity of the TRMs, thereby preventing an excessive immune reaction.
This research helps to elucidate the role played by the TRMs in the local reappearance of eczema patches. It also shows that the development of therapeutic strategies to prevent the local reactivation of the TRMs through their inhibitory receptors should open up new perspectives in the treatment of ACD.
In animals, a vaccine modifying the composition and function of the gut microbiota provides protection against the onset of chronic inflammatory bowel diseases and certain metabolic disorders, such as diabetes and obesity. ...
As tumors develop, they evolve genetically. How does the immune system act when faced with tumor cells? How does it exert pressure on the genetic diversity of cancer cells? Scientists from the Institut Pasteur and Inserm used in vivo video techniques and ...
Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy
Pia Gamradt, PhDa,b,c,d,e,∗, Léo Laoubi, MSca,b,c,d,e,∗, Audrey Nosbaum, MD, PhDa,b,c,d,e, Virginie Mutez, MSca,b,c,d,e, Vanina Lenief, MSca,b,c,d,e, Sophie Grande, MDf, Daniel Redoulès, PhDg, Anne-Marie Schmitt, MD, PhDh, Jean-François Nicolas, MD, PhDa,b,c,d,e,f, Marc Vocanson, PhDa,b,c,d,e,∗
a CIRI, International Center for Infectiology Research, Université de Lyon;
b INSERM, U1111, Lyon;
c Ecole Normale Supérieure de Lyon, Lyon;
d Université Lyon 1, Centre International de Recherche en Infectiologie, Lyon;
e CNRS, UMR 5308, Lyon;
f Allergology & Clinical Immunology, CH Lyon-Sud, Pierre-Benite;
g Pierre Fabre R&D Dermocosmétique, Toulouse;
h Pierre Fabre R&D Pharmaceuticals, Toulouse.
*These authors contributed equally to this work.
The Journal of Allergy and Clinical Immunology : https://doi.org/10.1016/j.jaci.2018.11.048